Association between biochemical and histopathological parameters in the clinical assessment of prostate tumors in a resource-limited setting in northern Cameroon

IF 3.5 Q3 Medicine

Cancer treatment and research communications Pub Date : 2026-01-01 Epub Date: 2026-03-11 DOI:10.1016/j.ctarc.2026.101175

Richard Tagne Simo , Larissa Pélagie Nodjia , Armel Hervé Nwabo Kamdje , Mohamadou Ahmadou , Franklin Danki Sillong , Phelix Bruno Telefo

{"title":"Association between biochemical and histopathological parameters in the clinical assessment of prostate tumors in a resource-limited setting in northern Cameroon","authors":"Richard Tagne Simo , Larissa Pélagie Nodjia , Armel Hervé Nwabo Kamdje , Mohamadou Ahmadou , Franklin Danki Sillong , Phelix Bruno Telefo","doi":"10.1016/j.ctarc.2026.101175","DOIUrl":null,"url":null,"abstract":"<div><div>In low-resource settings, prostate tumors are often diagnosed at advanced stages because of limited access to imaging and histopathological services. Identifying routinely available laboratory biomarkers that could support clinical assessment and referral decisions is therefore of practical importance. This study evaluated the associations between selected biochemical parameters and histopathological diagnoses of prostate tumors in northern Cameroon.</div><div>An analytical cross-sectional study was conducted among 90 men with suspected prostate tumors at the Islamic Clinic of Ngaoundere. Histopathological findings from prostate biopsy, including Gleason score, were correlated with serum prostate-specific antigen (PSA), creatinine, urea, and alkaline phosphatase (ALP). PSA was analyzed as both a continuous variable and a categorical variable using the standard 4 ng/mL threshold. Elevated creatinine was defined as ≥13 mg/L and urea as >0.5 mmol/L according to laboratory reference ranges.</div><div>Prostate cancer accounted for 48% of cases and benign prostatic hyperplasia (BPH) for 52%. The median PSA level was 27 ng/mL (range: 3–1706 ng/mL). PSA levels >4 ng/mL were observed in 65.6% of patients and were more frequent in prostate cancer (70.2%) than in BPH (60.5%), without significant discrimination (p = 0.331). Elevated creatinine and urea were found in 53.3% and 48.1% of patients, respectively. PSA, creatinine, and ALP were significantly associated with prostate volume, whereas urea was not. ALP elevation (30%) was not associated with Gleason score. Considerable overlap in biochemical values was observed between malignant and benign conditions.</div><div>Routinely available biochemical parameters provide complementary information but lack sufficient diagnostic accuracy to distinguish prostate cancer from BPH.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"Article 101175"},"PeriodicalIF":3.5000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294226000869","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

In low-resource settings, prostate tumors are often diagnosed at advanced stages because of limited access to imaging and histopathological services. Identifying routinely available laboratory biomarkers that could support clinical assessment and referral decisions is therefore of practical importance. This study evaluated the associations between selected biochemical parameters and histopathological diagnoses of prostate tumors in northern Cameroon.

An analytical cross-sectional study was conducted among 90 men with suspected prostate tumors at the Islamic Clinic of Ngaoundere. Histopathological findings from prostate biopsy, including Gleason score, were correlated with serum prostate-specific antigen (PSA), creatinine, urea, and alkaline phosphatase (ALP). PSA was analyzed as both a continuous variable and a categorical variable using the standard 4 ng/mL threshold. Elevated creatinine was defined as ≥13 mg/L and urea as >0.5 mmol/L according to laboratory reference ranges.

Prostate cancer accounted for 48% of cases and benign prostatic hyperplasia (BPH) for 52%. The median PSA level was 27 ng/mL (range: 3–1706 ng/mL). PSA levels >4 ng/mL were observed in 65.6% of patients and were more frequent in prostate cancer (70.2%) than in BPH (60.5%), without significant discrimination (p = 0.331). Elevated creatinine and urea were found in 53.3% and 48.1% of patients, respectively. PSA, creatinine, and ALP were significantly associated with prostate volume, whereas urea was not. ALP elevation (30%) was not associated with Gleason score. Considerable overlap in biochemical values was observed between malignant and benign conditions.

Routinely available biochemical parameters provide complementary information but lack sufficient diagnostic accuracy to distinguish prostate cancer from BPH.

查看原文本刊更多论文

在喀麦隆北部资源有限的环境中，前列腺肿瘤临床评估中的生化和组织病理学参数之间的关系。

在资源匮乏的环境中，由于影像和组织病理学服务的限制，前列腺肿瘤通常在晚期才被诊断出来。因此，确定常规可用的实验室生物标志物可以支持临床评估和转诊决定具有实际重要性。本研究评估了在喀麦隆北部选定的生化参数和前列腺肿瘤的组织病理学诊断之间的关系。在恩oundere伊斯兰诊所对90名疑似前列腺肿瘤的男性进行了一项分析性横断面研究。前列腺活检的组织病理学结果，包括Gleason评分，与血清前列腺特异性抗原（PSA）、肌酐、尿素和碱性磷酸酶（ALP）相关。使用标准4 ng/mL阈值分析PSA作为连续变量和分类变量。根据实验室参考范围，肌酐升高定义为≥13mg /L，尿素升高定义为>0.5 mmol/L。前列腺癌占48%，良性前列腺增生（BPH）占52%。中位PSA水平为27 ng/mL（范围：3-1706 ng/mL）。65.6%的患者PSA水平为bbbb4 ng/mL，前列腺癌（70.2%）高于前列腺增生（60.5%），差异无统计学意义（p = 0.331）。肌酐和尿素升高分别占53.3%和48.1%。PSA、肌酐和ALP与前列腺体积显著相关，而尿素与前列腺体积无关。ALP升高（30%）与Gleason评分无关。在恶性和良性条件之间观察到相当大的生化值重叠。常规可用的生化参数提供了补充信息，但缺乏足够的诊断准确性来区分前列腺癌和前列腺增生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer treatment and research communications Medicine-Oncology

CiteScore

4.30

自引率

0.00%

发文量

148

审稿时长

56 days

期刊介绍： Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.